Symposium on regression of atherosclerosis

European Journal of Clinical Investigation

Volumn 23, Issue 7, 1993, Pages 385-398

  MONCADA, S ^a   MARTIN, J F ^a   HIGGS, A ^a  

^a WELLCOME RESEARCH LABORATORIES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; PRIORITY JOURNAL; REVIEW; SYMPOSIUM;

ANGIOGRAPHY; ANIMAL; ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; FEMALE; HAPLORHINI; HUMAN; LIPOPROTEINS, LDL; MALE; MIDDLE AGE; RABBITS; RECURRENCE; REMISSION INDUCTION;

EID: 0027226143     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.1993.tb00781.x     Document Type: Review

References (89)

1. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults
2. The pathogenesis of atherosclerosis (second of two parts)
3. The pathogenesis of atherosclerosis–an update
4. Evidence for a monoclonal origin of human atherosclerotic plaques
5. Beyond cholesterol. Modifications of low‐density lipoprotein that increase its atherogenicity
6. Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis
7. Lipoproteins and atherogenesis
8. Virus induced atherosclerosis
9. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis
10. Neural factors contribute to atherogenesis
11. Arterial wall hypoxia following thrombosis of the vasa vasorum is an intimal lesion in atherosclerosis
12. Morphological characteristics of clinically significant coronary artery stenosis in stable angina
13. Compensatory enlargement of human atherosclerotic coronary arteries
14. Cross‐sectional area of the proximal portions of the three major epicardial coronary arteries in 90 necropsy patients with different coronary events. Relationship to heart weight, age and sex
15. Preservation of endothelium‐dependent vascular relaxation in cholesterol‐fed rabbit by treatment with the calcium blocker PN 200110
16. Effect of hypercholesterolemia on vascular reactivity in the rabbit. I. Endothehum‐dependent and endothelium‐independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits
17. Putative mechanisms of the impairment of endothelium‐dependent relaxation of the aorta with atheromatous plaque in heritable hyperlipidemic rabbits
18. Endothelium‐derived relaxing and contracting factors
19. Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys
20. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients
21. Effect of intracoronary serotonin on coronary vessels in patients with unstable angina and patients with variant angina
22. Vascular responses to leukocyte products in atherosclerotic primates
23. Mechanisms of contraction induced by human leukocytes in normal and atherosclerotic arteries
24. Nitric oxide: physiology, pathophysiology and pharmacology
25. Atherosclerosis impairs flow‐mediated dilation of coronary arteries in humans
26. Non‐invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis
27. Syndrome of symptomatic coronary arterial spasm with nearly normal coronary arteriograms
28. Platelets, endothelium and vasos‐pasm
29. Speculation regarding mechanisms responsible for acute ischemic heart disease syndromes
30. Hypothesis: Vasoconstriction contributes to amaurosis fugax
31. Restoration of endothelium‐dependent relaxation by dietary treatment of atherosclerosis
32. Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets
33. Arterial fibrous protein in cynomo‐lygous monkeys after atherogenic and regression diets
34. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis
35. Reflex constriction of significant coronary stenosis as a mechanism contributing to ischemic ventricular dysfunction during isometric exercise
36. Loss of flow‐mediated endothelium‐dependent dilation occurs early in the development of atherosclerosis
37. Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: Quantitative angiographic observations
38. Coronary arterial‐right heart fistulae: Long‐term observations in seven patients
39. Inhibitors of angioten‐sin‐converting enzyme prevent myointimal proliferation after vascular injury
40. Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF
41. Lovastatin prevents the impairment of endothelium dependent relaxation and inhibits accumulation of cholesterol in the aorta in experimental atherosclerosis in rabbits
42. Effect of lovastatin on intimal hyperplasia after balloon angioplasty: a study in an atherosclerotic hypercholesterolemic rabbit
43. Does the new angioten‐sin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR Study: a multicenter, randomized, double blind placebo‐controlled study
44. 2 and ADP
45. Regression of coronary atheromatosis in rhesus monkeys
46. A study of atherosclerosis regression in Macaca mulatta. V. changes in abdominal aorta and carotid and coronary arteries from animals with atherosclerosis induced for 38 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl
47. Dietary treatment of atherosclerosis abolishes hyperrespon‐siveness to serotonin: Implications for vasospasm
48. Vascular responses to activated leukocytes after regression of atherosclerosis
49. Hemodynamic sequelae of regression of experimental atherosclerosis
50. Psychosocial factors impair vascular responses of coronary arteries
51. Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation
52. Quantitative coronary angiography to measure progression and regression of coronary atherosclerosis. Value, limitations and implications for clinical trials
53. Constriction and dilatation in atherosclerotic and hypertensive arteries
54. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT)
55. A maximum confidence strategy for measuring progression and regression of coronary artery disease in clinical trials
56. Evaluation of colestipol/niacin therapy with computer‐derived coronary end‐point measures. A comparison of different measures of treatment effect
57. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries
58. The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non‐randomized controlled study
59. Detection of coronary atherosclerosis in young adult hearts using intravascular ultrasound
60. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterole‐mia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
61. Development of femoral atherosclerosis in hypercholesteroleniic patients during treatment with cholestyramine and probucol, placebo: Probucol Quantitative Regression Swedish Trial (PQRST): A Status Report
62. Regression of femoral atherosclerosis
63. Beneficial effects of combined colestipol‐niacin therapy on coronary atherosclerosis and coronary venous bypass grafts
64. Beneficial effects of colestipol‐niacin on coronary atherosclerosis. A 4–year follow up
65. Coronary atheroma regression trials
66. Regression of coronary artery disease as a result of intensive lipid‐lowering therapy in men with high levels of apolipoprotein B
67. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens
68. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial
69. Regression of atherosclerosis. Benefit can be expected from low LDL‐C and high HDL‐C levels (Editorial)
70. Is cholesterol reduction always safe?
71. Serum cholesterol–the knave of hearts and the joker
72. Glucose tolerance, plasma insulin, HDL cholesterol and obesity: 12 year follow‐up and development of coronary heart disease in Edinburgh men
73. The effects of fat and cholesterol on social behavior in monkeys
74. Plasma cholesterol and depressive symptoms in older men
75. Clinical perspective of trials of regression of coronary atherosclerosis
76. Chewing the fat–how much and what kind
77. Health policy on blood cholesterol. Time to change directions (editorial)
78. Cigarette smoking, social class and nutrient intake. Relevance to coronary heart disease
79. Cigarette smoking, polyunsaturated fats, linoleic acid, and coronary heart disease
80. Prediction of angiographic changes in native human coronary arteries and aortocoronary bypass grafts. Lipid and neolipid factors
81. The effects on plasma lipoproteins of a prudent weight‐reducing diet, with or without exercise, in overweight men and women
82. Modest changes in high‐density lipoprotein concentration and metabolism with prolonged exercise training
83. HDL cholesterol and other lipids in coronary heart disease
84. The pathogenesis of atherosclerosis: a perspective for the 1990s
85. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis
86. Cellular mechanisms of atherogenesis and the effects of nitric oxide
87. Correlation of endothelial dysfunction in coronary microcirculation of hyper‐cholesterolaemic patients
88. L‐arginine improves endothelium‐dependent vasodilation in hypercholesterolemic humans
89. Assessment of short‐, medium‐, and long‐term variations in arterial dimensions from computer‐assisted quantification of coronary cineangio‐grams